John A. Bittl et al. JACC 2016;68:

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:

Flow diagram of the systematic literature search indicating the inclusion and exclusion process of studies Liakopoulos OJ, et al. Eur Heart J 2008;29:

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Date of download: 7/8/2016 From: Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Current Problems in Cardiology

Figure 1 Ischaemic endpoints

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Randomisation before planned PCI with DES (n=2500)

Robert A. Guyton, MD The Annals of Thoracic Surgery

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

Incremental Value of the CRUSADE, ACUITY, and HAS‐BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Glenn N. Levine et al. JACC 2016;68:

Robert W. Yeh et al. JACC 2017;70:

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Robert A. Guyton, MD The Annals of Thoracic Surgery

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Konstantinos C. Siontis et al. JACEP 2016;2:

Dean J. Kereiakes et al. JACC 2017;70:

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Ashish Shukla et al. JACEP 2015;1:41-51

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome Abhishek Sharma, MD,

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

David J.A. Jenkins et al. JACC 2018;71:

Tornado diagram of one-way deterministic sensitivity analysis.

Mintu P. Turakhia et al. JACEP 2016;2:

Konstantinos C. Siontis et al. JACEP 2016;2:

Matthew Oster et al. JACC 2019;73:

Svend A. Mortensen et al. JCHF 2014;2:

Prabhat Kumar et al. JACEP 2016;j.jacep

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Seung-Yul Lee et al. JCIN 2018;j.jcin

Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Giuseppe Gargiulo et al. JACC 2018;71:

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Saadia Sherazi et al. JACEP 2015;1:74-80

Maria Alejandra Restrepo-Cordoba et al. JCIN 2016;9:e137-e139

Zachary L. Steinberg et al. JACC 2017;69:

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Christian Madelaire et al. JCHF 2018;6:

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Pamela E. Scott et al. JACC 2018;71:

Jeffrey Senfield et al. JACEP 2017;3:

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Orly Vardeny et al. JCHF 2016;4:

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

John A. Bittl et al. JACC 2016;68:1116-1139 Forest Plot of Endpoints After 12 Months Versus Shorter Courses of DAPT After DES Implantation Forest plots of mortality rate (A), major hemorrhage (B), myocardial infarction (C), stent thrombosis (D), and primary study endpoints (E) after 12-month course versus shorter course of dual antiplatelet therapy after drug-eluting stent implantation. Study acronyms (16–18,20,22) are defined in Table 1. CI indicates confidence interval; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; and OR, odds ratio. John A. Bittl et al. JACC 2016;68:1116-1139 2016 American College of Cardiology Foundation and the American Heart Association, Inc.